A role of TRPA1 in mechanical hyperalgesia is revealed by pharmacological inhibition.
Petrus M, Peier AM, Bandell M, Hwang SW, Huynh T, Olney N, Jegla T, Patapoutian A. · 2007
Read A role of TRPA1 in mechanical hyperalgesia is revealed by pharmacological inhibition. by Petrus M, Peier AM, Bandell M, Hwang SW, Huynh T, Olney N, Jegla T, Patapoutian A. (2007) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/europmc-pmc2222610.txt.
Introduction
Petrus and co-workers showed in 2007 that blocking an ion channel called TRPA1 reverses mechanical hyperalgesia, an exaggerated pain response to pressure. TRPA1 senses pungent chemicals and may detect harmful mechanical and cold stimuli. Its role in sensitised pain was unsettled. The team developed a specific small-molecule blocker, AP18, and tested it in mice with inflammation caused by complete Freund's adjuvant, a standard pain model.
AP18 reduced pain behaviour triggered by cinnamaldehyde, a TRPA1 activator. It also reversed the inflammation-induced mechanical hyperalgesia in normal mice. In mice genetically lacking TRPA1, hyperalgesia developed normally, yet AP18 had no effect there, proving the drug acts on target. The authors infer that TRPA1 helps sensitise pain, and that lifelong knockout mice compensate in ways that mask that role.
Catalog record
| CREATOR | Petrus M, Peier AM, Bandell M, Hwang SW, Huynh T, Olney N, Jegla T, Patapoutian A. |
|---|---|
| YEAR | 2007 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 26 KB |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |
Browse the full library · About the Tower of Babel
Full text
The opening of the work, from the library's hosted text:
A role of TRPA1 in mechanical hyperalgesia is revealed by pharmacological inhibition By Matt Petrus, Andrea M Peier, Michael Bandell, Sun Wook Hwang, Truc Huynh, Nicholas Olney, Tim Jegla, Ardem Patapoutian Published in: Molecular Pain DOI: 10.1186/1744-8069-3-40 ABSTRACT Abstract Mechanical hyperalgesia is a clinically-relevant form of pain sensitization that develops through largely unknown mechanisms. TRPA1, a Transient Receptor Potential ion channel, is a sensor of pungent chemicals that may play a role in acute noxious mechanosensation and cold thermosensation. We have developed a specific small molecule TRPA1 inhibitor (AP18) that can reduce cinnameldehyde-induced nociception in vivo. Interestingly, AP18 is capable of reversing CFA-induced mechanical hyperalgesia in mice. Although TRPA1-deficient mice develop normal CFA-induced hyperalgeisa, AP18 is ineffective in the knockout mice, consistent with an on-target mechanism. Therefore, TRPA1 plays a role in sensitization of nociception, and that compensation in TRPA1-deficient mice masks this requirement. BACKGROUND Sensory neurons of the dorsal root ganglia (DRGs) can detect environmental changes through projections in the skin. Among these primary afferent fibers, nociceptors play an important role in sensing noxious levels of mechanical and thermal stimuli [1]. One of the basic properties of nociceptors is their sensitization in response to injury and inflammation. For example, an innocuous stimulus such as a warm shower can become painful after sunburn, and this is called allodynia. Indeed, cold or mechanical allodynia are serious medical problems for patients suffering from neuropathic pain [2,3]. Hyperalgesia describes a similar condition, defined as an increased response to an already painful stimulus due to injury or inflammation. TRPV1, a member of the Transient Receptor Potential family of cation channels, is activated by heat, low pH, and capsaicin [4]. TRPV1 is expressed in nociceptors, and is sensitized in response to a variety of signal transduction pathways activated during inflammation [5,6]. TRPV1-deficient mice display negligible inflammatory heat hyperalgesia [7,8]. Much less is known about molecules involved in mechanical hyperalgesia. Originally characterized as a noxious cold-activated ion channel, TRPA1 is expressed in the same sensory neurons as TRPV1, and is activated directly by diverse reactive chemicals via covalent modification, and indirectly through G-protein coupled receptors [9-12]. TRPA1 is required to sense these noxious reactive chemicals in vivo; however, whether TRPA1 is required to sense acute noxious cold and mechanical stimulus is not yet settled [13-17]. Here, we examine the consequences of acute block of peripheral TRPA1 for pain transduction, focusing on mechanical hyperalgesia. RESULTS To test if acute block of TRPA1 can modulate pain sensation, we sought a specific, efficient TRPA1 inhibitor. Ruthenium red, gadolinium, menthol, and camphor can inhibit TRPA1 activation, but also interact with other channels, including other TRP channels[18]. Using a Fluorometric Imaging Plate Reader (FLIPR, Molecular Devices) calcium-influx assay, we screened 43,648 small molecules for their ability to block cinnamaldehyde-activation of human TRPA1 in a Chinese Hamster Ovary (CHO) cell line. We further characterized one of these hits, AP18 ((Z)-4-(4-chlorophynyl)-3-methylbut-3-en-2-oxime – Maybridge, Cornwall, UK; Figure 1A). AP18 blocked activation of TRPA1 by 50 μM cinnamaldehyde with an IC50 of 3.1 μM and 4.5 μM for human and mouse clones, respectively (Figure 1B). At concentrations up to 50 μM, AP18 was unable to appreciably block activation of TRPV1, TRPV2, TRPV3, TRPV4, or TRPM8 (Figure 2). AP18 reversibly blocked mouse TRPA1 responses to iodoacetamide (an irreversible cysteine-alkylating agent) in CHO cells assayed by ratiometric Ca2+ imaging (Figure 1C). AP18 also blocked cold- and mustard-oil-induced activation of mouse TRPA1 (data not shown). Moreover, AP18 blocked cinnamaldehyde-induced TRPA1 currents in excised patches from Xenopus oocytes (Figure 1D). In vivo, 1–10 mM of AP18 injected in hindpaw of mice did not cause any obvious behavioural responses (data not shown). Importantly, AP18 significantly blocked cinnamaldehdye-induced but not capsaicin-induced nociceptive events, demonstrating efficacy and specificity (Figure 3). [Figure: AP18 blocks TRPA1 activation. (A) Chemical structures of the AP18 (upper) and cinnamaldehyde (lower). (B) Dose-response relationships for block of the calcium influx by AP18 into CHO cells expressing mouse and human TRPA1 elicited by 50 μM cinnamaldehyde (left panel). Calcium influx was measured using a standard FLIPR assay, data points are the average of four wells (~8,000 cells/well) and error bars show standard error. Values are normalized to the maximal response (observed in the absence of AP18). (C) Ratiometric Ca2+ imaging of average of ~50 mTRPA1-expressing CHO cells in response to 1 mM Iodoacetamide (IA) and 100 μM of AP18 (black trace). Grey trace represents cells that were treated with IA alone. (D) Current-voltage relationship of TRPA1. Outward rectifying currents elicited by cinnamaldehyde (left panel) in inside-out macropatches derived from TRPA1-expressing Xenopus oocytes were suppressed by AP18 coapplications (right panel).] [Figure: AP18 specifically blocks TRPA1. Calcium influx (FLIPR) in HEK cells transiently transfected with the indicated cDNAs in response to 200 nM capsaicin (TRPV1), 150 μM 2-APB (TRPV2), 30 μM 2-APB (TRPV3), 20 μM 4alpha-PDD (TRPV4), 20 μM menthol (TRPM8), and 80 μM cinnamaldehyde (TRPA1). Values are given as a percentage of agonist response in the absence of AP18.] [Figure: AP18 suppresses acute nociceptive behaviours caused by cinnamaldehyde but not capsaicin. Time spent licking and flicking hindpaws injected with cinnamaldehyde (16.4 mM) or capsaicin (0.328 mM) was measured for five minutes and compared with animals co-injected with AP18 (1 mM). Numbers of cases for each experiment from the left is 8, 8, 6 and 6, respectively (*p < 0.05, two-tailed Student's t-test).] Sensitization of nociceptive neurons is the basis for many chronic pain states [1]. To investigate the role of TRPA1 in pain sensitization, we tested AP18 in mechanical hyperalgesia induced by complete Freund's adjuvant (CFA). Mechanical sensitivity was measured using an automated Von Frey apparatus which records the point at which the paw is withdrawn in response to a progressively-increasing force. AP18 but not vehicle solution injected in the paw 24 hours after CFA treatment almost completely reversed mechanical hyperalgesia (Figure 4A). AP18 did not reverse CFA-induced heat hyperalgesia (Figure 5). Acute nociceptive responses to both increasing mechanical force and infrared noxious heat applications to the paw without coincident inflammation were not affected by AP18 treatment (data not shown). Remarkably, AP18 did not reverse CFA-induced mechanical hyperalgesia in TRPA1-deficient mice, suggesting on-target mechanisms for the activity of AP18 (Figure 4B) [16,17]. It is important to note that prior to AP18 treatment, TRPA1-deficient mice developed normal CFA-induced mechanical hyperalgesia (Figure 4B), suggesting that compensation in these mice masks the requirement for TRPA1 in mechanical sensitization (see discussion below). Also note that TRPA1-deficient mice do not show significantly increased acute mechanical threshold before CFA application in this assay (Figure 4B). However, we do observe the previously-reported deficit in acute mechanosensation in TRPA1-deficient mice at higher g-forces when using the protocol of Kwan et al.(2006) which assays frequency of paw withdrawal in response to a fixed (rather than increasing) force applied to the paw (Figure 6) [16]. In addition to the acute mechanosensory phenotype, TRPA1-deficient mice have strong deficits in bradykinin-induced inflammatory pain [16,17]. As expected, AP18-treated mice showed reduced bradykinin-induced mechanical hyperalgesia compared to vehicle (Figure 7). [Figure: TRPA1 is involved in CFA-induced mechanical hyperalgesia. (A) AP18 reverses CFA-induced mechanical hyperalgseia in wildtype mice (n = 8). Red symbols represent the paws treated with CFA. 24 hours later, mechanical sensitivity was assayed again ("after CFA" timepoint), and the same paws were